#1

From the GRG mailing list (I know nothing about the group below):

Good day! I hope this message finds you well. I’m reaching out to you about an FDA and IRB approved clinical trial with young plasma, specifically G-CSF Mobilized Fresh Frozen Plasma (GMFFP), led by Dr. Dipnarine Maharaj, that we are running at the Maharaj Institute of Immune Regenerative Medicine in South Florida (Study Details | Safety, Efficacy of FFP From Healthy Donors to AmeliorateFrailty and Enhance Immune Function in Older Individuals | ClinicalTrials.gov). My name is Kurt Whittemore, and you may also be aware of my previous work doing telomere aging research in the lab of Dr. Maria Blasco.

The following message has been approved by Sterling IRB, IRB ID: 9120.

We’re reaching out with a chance for you or a loved one to participate in our study aimed at reducing the effects of an aging immune system!

Young blood plasma enriched with proteins from their stem cells: Our study is exploring the possible benefits of young blood plasma from healthy donors, aiming to help improve the immune system of aged individuals between 55 to 95 years.

Stem cell enriched proteins in plasma : The young donors receive granulocyte colony-stimulating factor (G-CSF), releasing their stem cells into the blood, creating G-CSF Mobilized Fresh Frozen Plasma (GMFFP).

Potential of Stem Cell Enriched Proteins in Plasma: Harvested from healthy donors, plasma has the potential to restore immune function and combat frailty in older individuals.

FDA-Approved and IRB Study : Our study, using GMFFP, has received approval from the FDA and IRB to enroll participants to evaluate its safety and effectiveness. The use of GMFFP in this study is investigational and is not approved by the FDA.

Frailty Wanted: We are seeking participants identified as “frail” to receive GMFFP, evaluating its safety and effectiveness in managing frailty symptoms.

Two-Year Study: Embark on a two-year journey with personalized medical attention, testing, and explanations tailored just for you.

Shape the Future: By participating, you’re not just helping to possibly improve frailty; you’re contributing to future medical research.

If you’re ready to be a part of this exciting quest or have any questions, please don’t hesitate to reach out to us at 561-752-5522 or kwhittemore@bmscti.org.

Thank you for considering this opportunity to help make a difference in the world of aging and immune health.

We look forward to having you on board!

Best regards,

Dr. Dipnarine Maharaj MD PhD FACP, Medical Director

Dr. Kurt Whittemore PhD, Specialist Project Manager

South Florida Bone Marrow Stem Cell Transplant Institute

DBA Maharaj Institute of Immune Regenerative Medicine

10301 Hagen Ranch Rd Ste. 600

Boynton Beach, FL 33437 USA

Phone: 561-752-5522

Fax: 561-752-5446

5 Likes
#2

I thought the 3 papers simultaneously released in Nature, (Platelet factors are induced by longevity factor klotho and enhance cognition in young and aging mice | Nature Aging) put the need to infuse young plasma to rest (and obviously mitigate the risk of disease transmission).
All 3 papers showed platelet factor 4 (PF4), either alone or with Klotho were the primary factor. Recombinant PF4 is readily obtainable and has been used by surgeons in the OR since 2004, with a wide range of doses used and published (in humans!). I have wondered why the Klotho crowd putters around trying to purchase Klotho and guess what pgm dose might not be homeopathic and doesn’t just order PF4 and get the party started.
Recombinant platelet factor 4 for heparin neutralization (Recombinant platelet factor 4 for heparin neutralization - PubMed.

#3

Do you have any experience with this yourself? If I may ask